When it comes to investing in the healthcare sector there are a handful of companies which enjoy ‘market darling’ status.

Amongst these high quality but richly priced stocks are Ramsay Health Care Limited (ASX: RHC) and CSL Limited (ASX: CSL).

There is little argument that these businesses own some appealing assets. The problem for investors who demand a margin of safety in their purchase price is that these stocks trade at levels which leave very little room for anything but perfection.

Enter Sonic Healthcare Limited (ASX: SHL).

Sonic is a much smaller company than either Ramsay or CSL, with a market capitalisation of $7.6 billion.

From a price compared to value point-of-view however, it is arguably more appealing…

The group is a provider of medical diagnostic services – a market segment in which it competes with the likes of Primary Health Care Limited (ASX: PRY) and Healthscope Ltd (ASX: HSO).

Unlike Primary and Healthscope however, Sonic boasts major overseas operations (particularly the USA and Germany) which contribute over half of the total revenues to the group.

This is currently providing an earnings tailwind thanks to the weaker Australian dollar while also providing important diversification of regulatory risks too.

At the interim financial results presentation in February, management provided guidance for earnings before interest, tax, depreciation and amortisation (EBITDA) growth of over 25% to a range between $870 million to $900 million at current exchange rates.

At the earnings per share (EPS) level, one analyst consensus suggests EPS should rise from 86.6 cents per share (cps) in FY 2015 to 106.9 cps in FY 2016. (Source: CommSec)

With the share price slipping around 10% in the past 12 months – that’s slightly less than the 15% decline in the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) – the stock is trading on a forecast price-to-earnings ratio of 17.2 times.

While investors should be mindful of the lower franking of Sonic’s earnings, this is arguably still an attractive multiple to acquire a high quality, defensive business on.

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

Forget BHP and Woolworths. These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tim McArthur has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.